Gilead Sciences, Inc. (GILD) – A Growing Focus On Cancer

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Gilead Sciences, Inc. (GILD) (Q4FY22)

Highlights

GILD revenues were $27.3bn in FY22 and remained relatively flat compared to FY21, primarily due to increased sales in HIV, cell therapy and Trodelvy, offset by lower sales of Veklury. Total fourth quarter 2022 revenue of $7.4bn increased 2% compared to the same period in 2021, primarily due to increased sales in Oncology, HIV and hepatitis C virus (“HCV”), partially offset by lower Veklury® (remdesivir) sales.

In 2022, the company incurred expenses related to acquired in-process research and development (IPR&D) as a result of various business development (BD) transactions. The
company collaborated with Dragonfly, it acquired MiroBio and collaborated with MacroGenics.

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 39

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates